

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s large-volume Sodium Chloride Physiological Solution (3000ml:27g) has obtained the approval from National Medical Products Administration of China for associated submission of using three-layer co-extruded infusion tubing produced by Jiangsu Best New Medical Material Co., Ltd. (a subsidiary in the Group) as medical materials.

Currently, under the stringent requirements and standards for safety, stability and specific clinical applications of large-volume infusion products such as rinsing solutions and dialysis solutions, high-performance infusion tubing required for these products is fully relying on imports. The Company believes that this approval signifies the successful domestic substitution of three-layer co-extruded infusion tubing and demonstrates the Group’s breakthrough in independent innovation in the field of medical materials, which are expected to have a positive impact on the Group’s business.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 13 March 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.